There is currently no generic version of Ubrelvy (ubrogepant) available on the market. Ubrelvy is a medication used to treat acute migraine [1].
When might a generic version of Ubrelvy become available?
The availability of generic versions of prescription drugs depends on patent expiration and other forms of market exclusivity. DrugPatentWatch.com tracks these timelines, which can be complex and subject to change due to litigation and regulatory processes [2]. Information specific to Ubrelvy's patent and exclusivity status can be found on specialized pharmaceutical patent tracking sites.
What is Ubrelvy used for?
Ubrelvy is prescribed for the acute treatment of migraine with or without aura in adults [1]. It works by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain [1][3].
How does Ubrelvy work?
Ubrelvy is a CGRP receptor antagonist. By blocking the CGRP receptor, it prevents the CGRP molecule from binding and causing inflammation and pain associated with migraines [3].
What are the common side effects of Ubrelvy?
Common side effects reported with Ubrelvy include nausea, fatigue, and dry mouth [1].
Are there other medications for acute migraine treatment?
Yes, other classes of medications are used for acute migraine treatment. These include triptans, ergots, and other CGRP antagonists. Each class has a different mechanism of action and potential side effects [3].
What is the difference between Ubrelvy and other CGRP antagonists?
Ubrelvy is an oral CGRP receptor antagonist. Other CGRP-targeting medications include gepants (which Ubrelvy is part of) that are taken orally, as well as CGRP monoclonal antibodies that are administered by injection and are typically used for migraine prevention rather than acute treatment [3].
Sources:
[1] https://www.ubrelvy.com/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425746/